FDA conditionally recommends approval for amyloid imaging technology

A U.S. Food and Drug Administration (FDA) advisory panel last week said that florbetapir (Amyvid), a radioactive dye proposed for use in Positron Emission Tomography (PET) to detect amyloid buildup in the brain, could be useful pending additional data analysis and training for physicians. The Alzheimer’s Association believes that further research is needed to understand the appropriate use of florbetapir-PET imaging — or any other imaging technology — in diagnosing Alzheimer’s. Read more here: http://bit.ly/huzUgV

POST A COMMENT: Please continue the conversation here in the comments section of our blog. We welcome all viewpoints, but encourage you to be constructive. Any opinions, advice, statements or other information contained in the following comments are the responsibility of the author of that message and not of the Alzheimer’s Association. The Alzheimer’s Association does not in any way endorse, verify the accuracy, completeness or usefulness of any messages posted in the comments section. The comments are moderated and we will make every effort to review and post them as promptly as possible.

Copyright © 2013 Alzheimer's Association. All Rights Reserved.

Through this website you are able to link to other websites which are not under the control of the Alzheimer’s Association. We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.

Chapter Headquarters
Alzheimer's Association of Northern California and Northern Nevada
1060 La Avenida, Mountain View, CA 94043 Phone 650.962.8111

National Headquarters
Alzheimer's Association National Office 225 N. Michigan Ave., Fl. 17, Chicago, IL 60601 Alzheimers and Dementia Blog – Alzheimers Association of Northern California and Northern Nevada

Built on Notes Blog Core
Powered by WordPress